O	0	1	[	[	(	O
O	1	20	Retinochoroidopathy	Retinochoroidopathy	NN	B-NP
O	21	26	after	after	IN	B-PP
O	27	39	intravitreal	intravitreal	JJ	B-NP
O	40	44	anti	anti	AFX	I-NP
O	44	45	-	-	HYPH	I-NP
O	45	49	VEGF	VEGF	NN	I-NP
O	50	59	treatment	treatment	NN	I-NP
O	59	60	]	]	)	O

O	61	62	A	A	DT	B-NP
O	63	65	74	74	CD	I-NP
O	65	66	-	-	HYPH	I-NP
O	66	70	year	year	NN	I-NP
O	70	71	-	-	HYPH	O
O	71	74	old	old	JJ	B-NP
O	75	78	man	man	NN	I-NP
O	79	88	presented	present	VBN	B-VP
O	89	93	with	with	IN	B-PP
O	94	104	persistent	persistent	JJ	B-NP
O	105	120	metamorphopsias	metamorphopsia	NNS	I-NP
O	121	123	of	of	IN	B-PP
O	124	127	the	the	DT	B-NP
B-Organ	128	133	right	right	JJ	I-NP
I-Organ	134	137	eye	eye	NN	I-NP
O	138	139	2	2	CD	B-NP
O	140	145	weeks	week	NNS	I-NP
O	146	151	after	after	IN	B-PP
O	152	164	intravitreal	intravitreal	JJ	B-NP
O	165	174	injection	injection	NN	I-NP
O	175	177	of	of	IN	B-PP
O	178	189	bevacizumab	bevacizumab	NN	B-NP
O	190	192	to	to	TO	B-VP
O	193	198	treat	treat	VB	I-VP
B-Multi-tissue_structure	199	208	choroidal	choroidal	JJ	B-NP
O	209	227	neovascularization	neovascularization	NN	I-NP
O	228	231	due	due	JJ	B-PP
O	232	234	to	to	TO	B-PP
O	235	244	exudative	exudative	JJ	B-NP
O	245	248	age	age	NN	I-NP
O	248	249	-	-	HYPH	O
O	249	256	related	relate	VBN	B-NP
B-Tissue	257	264	macular	macular	JJ	I-NP
O	265	277	degeneration	degeneration	NN	I-NP
O	277	278	.	.	.	O

O	279	282	The	The	DT	B-NP
O	283	292	diagnosis	diagnosis	NN	I-NP
O	293	300	reached	reach	VBN	B-VP
O	301	304	was	be	VBD	B-VP
O	305	322	retinochoroiditis	retinochoroiditis	NN	B-NP
O	323	325	as	as	IN	B-PP
O	326	328	an	an	DT	B-NP
O	329	335	occult	occult	JJ	I-NP
O	336	349	manifestation	manifestation	NN	I-NP
O	350	352	of	of	IN	B-PP
O	353	364	sarcoidosis	sarcoidosis	NN	B-NP
O	364	365	,	,	,	O
O	366	374	possibly	possibly	RB	B-ADVP
O	375	384	resulting	result	VBG	B-VP
O	385	389	from	from	IN	B-PP
O	390	392	an	an	DT	B-NP
O	393	405	intravitreal	intravitreal	JJ	I-NP
O	406	415	injection	injection	NN	I-NP
O	416	418	of	of	IN	B-PP
O	419	430	bevacizumab	bevacizumab	NN	B-NP
O	430	431	.	.	.	O

O	432	435	The	The	DT	B-NP
O	436	443	patient	patient	NN	I-NP
O	444	452	received	receive	VBD	B-VP
O	453	454	a	a	DT	B-NP
O	455	467	prescription	prescription	NN	I-NP
O	468	471	for	for	IN	B-PP
O	472	475	100	100	CD	B-NP
O	476	478	mg	mg	NN	I-NP
O	479	487	Ultralan	Ultralan	NNP	I-NP
O	488	490	to	to	TO	B-VP
O	491	493	be	be	VB	I-VP
O	494	499	taken	take	VBN	I-VP
O	500	505	daily	daily	RB	B-ADVP
O	506	509	for	for	IN	B-PP
O	510	511	3	3	CD	B-NP
O	512	516	days	day	NNS	I-NP
O	517	520	and	and	CC	O
O	521	525	then	then	RB	B-VP
O	526	533	tapered	taper	VBN	I-VP
O	534	536	in	in	IN	B-PP
O	537	538	3	3	CD	B-NP
O	539	542	day	day	NN	I-NP
O	543	548	steps	step	NNS	I-NP
O	548	549	.	.	.	O

O	550	556	During	During	IN	B-PP
O	557	560	the	the	DT	B-NP
O	561	568	further	further	JJ	I-NP
O	569	575	course	course	NN	I-NP
O	576	578	no	no	DT	B-NP
O	579	592	deterioration	deterioration	NN	I-NP
O	593	595	of	of	IN	B-PP
O	596	599	the	the	DT	B-NP
O	600	609	condition	condition	NN	I-NP
O	610	613	was	be	VBD	B-VP
O	614	622	observed	observe	VBN	I-VP
O	622	623	.	.	.	O

